$AGN.C is seeing some consolidation after last week’s big run as some investors take profits on their gains. Their model of using approved, safe, and well-established drugs for undiscovered uses has already shown great promise over the past few months as their research trials continue to move forward. Recent results from the phase 2 Ifenprodil IPF/Chronic Cough study found positive results for both treatments. With only 2 existing IPF treatments costing tens of thousands of dollars, $AGN.C has considerable market potential once they reach approval.
Not only do they have a potential drug for IPF/Chronic Cough, but $AGN.C is also researching into the use of DMT microdoses to help stroke victims with preclinical work concluded and evidence to support that DMT is effective in promoting neurogenesis and synaptic growth. Additionally, they're developing reprinast for treating chronic kidney disease, which has shown to decrease fibrosis significantly.
Considering that their drug development targets multiple multi-billion dollar markets, there's significant room for upside, especially with the recently placed $25 price target. Keep an eye out for the film phase 2a Ifenprodil IPF results in Q3, phase 1 studies for Repirinast, DMT, and Ifenprodil (for cancer treatments) in Q4, and phase 2b of Ifenprodil for IPF during mid-2023. Only an $8M valuation here, and looking at all these potential catalysts, definitely keep an eye out for future developments.